Literature DB >> 19119630

[The expression of fibrillin 1 in pathologic scars and its significance].

Fang-Fei Nie1, Qi Wang, Ze-Lian Qin.   

Abstract

OBJECTIVE: To probe into the mechanism of fibrillin 1 in pathologic scar, by examining the expressions of fibrillin 1 and TGF-beta1 as well as their correlations in the tissues of keloid, hypertrophic scar and normal skin.
METHODS: The tissues of keloid, hypertrophic scar and normal skin were tested. RT-PCR was used to assess the mRNA expression levels of the aimed genes. The distribution of fibrillin 1 in scars and normal skin was examined by immunohistochemistry staining.
RESULTS: The mRNA level of fibrillin 1 in keloid (0.802 +/- 0.116) was increased by 218.25% (P < 0.01) than that in normal skin (0.252 +/- 0.067). The expression of the gene in hypertrophic scar (0.628 +/- 0.144) was higher by 149.21% (while, P > 0.05) than that in normal skin. The expression of TGF-beta1 in keloid and hypertrophic scar were more than that in normal skin. The expression of fibrillin 1 was related to that of TGF-beta1 positively (r = 0.820, P < 0.01). Fibrillin 1 protein was stained positively in basic membranes, endothelial cells, fibroblasts and extracellular matrix of skin tissues. In dermal, the protein levels of fibrillin 1 in keloid (0.117 +/- 0.042) was decreased than those in normal skin (0.185 +/- 0.043) and hypertrophic scar (0.181 +/- 0.048), the inhibition rates were 36.76%, 35.36% respectively (both P < 0.01).
CONCLUSIONS: The expression of fibrillin 1 in keloid was changed and related to the expression of TGF-beta1 positively, which appears that fibrillin 1 was a cicatrix specific gene. Fibrillin 1 might play an important role in the formation of keloid.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19119630

Source DB:  PubMed          Journal:  Zhonghua Zheng Xing Wai Ke Za Zhi        ISSN: 1009-4598


  1 in total

Review 1.  New molecular medicine-based scar management strategies.

Authors:  Anna I Arno; Gerd G Gauglitz; Juan P Barret; Marc G Jeschke
Journal:  Burns       Date:  2014-01-15       Impact factor: 2.744

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.